VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
NUWE
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
NUWENuwellis, Inc.
$3.29$1M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

NUWE logoNuwellis, Inc.(NUWE)Earnings, Financials & Key Ratios

NUWE•NASDAQ
$3.14
Price updated Jul 2, 2026
SectorHealthcareIndustryMedical DevicesSub-IndustryRenal, dialysis, and blood purification
AboutNuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.Show more
  • Revenue$8M-5.4%
  • EBITDA-$11M-0.1%
  • Net Income-$18M-56.9%
  • EPS (Diluted)-25.39+90.9%
  • Gross Margin61.96%-7.1%
  • EBITDA Margin-129.25%-5.8%
  • Operating Margin-134.29%-6.8%
  • Net Margin-211.86%-65.8%
  • ROE-382.81%-67.0%

NUWE Price & Volume

Nuwellis, Inc. (NUWE) stock price & volume — 10-year historical chart

Loading chart...

Persistent Operational Burn Threatens Nuwellis Solvency

Investment Thesis • Updated 2026Q1

VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity shortfall

Key Thesis Takeaways

  • Nuwellis faces a precarious financial outlook characterized by a decade of persistent net losses and a cumulative deficit exceeding $320M in retained earnings.
  • While the company maintains a 70.1% gross margin as of 2026Q1, its inability to scale revenue beyond $2.4M per quarter while managing high SG&A costs suggests a structural failure to achieve profitability.
  • Investors should exercise extreme caution given the company's reliance on minimal cash reserves of $2.1M and the high probability of future dilutive financing to sustain operations.

Verdict Logic

the company's precarious liquidity position, highlighted by a cash balance of only $2.1M against a history of consistent quarterly cash outflows, suggests an imminent risk of insolvency or significant shareholder dilution.

NUWE Growth Metrics

Nuwellis, Inc. (NUWE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years63.93%
5 Years2.14%
3 Years-1.08%
TTM-0.2%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-91.34%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-220.59%

Return on Capital

10 Years-173.97%
5 Years-133.42%
3 Years-168.16%
Last Year-213.76%

NUWE Recent Earnings

Nuwellis, Inc. (NUWE) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
May 12, 2026
Metric
Actual
Est
EPS
$2.09-109.0%
$1.00
Rev
$2M+14.8%
$2M
Q2 2026
Mar 10, 2026
Metric
Actual
Est
EPS
$1.50+3.8%
$1.56
Rev
$2M+4.9%
$2M
Q4 2025
Nov 12, 2025
Metric
Actual
Est
EPS
$0.56+103.3%
$17.22
Rev
$2M-4.0%
$2M
Q3 2025
Aug 14, 2025
Metric
Actual
Est
EPS
$60.99-222.7%
$18.90
Rev
$2M-21.6%
$2M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 12, 2026
$2.09vs $1.00-109.0%
$2Mvs $2M+14.8%
Q2 2026Mar 10, 2026
$1.50vs $1.56+3.8%
$2Mvs $2M+4.9%
Q4 2025Nov 12, 2025
$0.56vs $17.22+103.3%
$2Mvs $2M-4.0%
Q3 2025Aug 14, 2025
$60.99vs $18.90-222.7%
$2Mvs $2M-21.6%
Based on last 12 quarters of dataView full earnings history →

Latest NUWE News

Recent stock market news and headlines for Nuwellis, Inc. (NUWE)

GlobeNewsWire·Jun 26, 2026
Nuwellis Celebrates Five Years of Support of the Pediatric Cardiac Critical Care Consortium (PC⁴)

MINNEAPOLIS, June 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces the five-year anniversary of its support of the annual conference for the Pediatric Cardiac Critical Care Consortium (PC4 ), an alliance aiming to improve the quality of care to patients with critical pediatric and congenital cardiovascular disease. Over the past five years, Nuwellis has collaborated with leading pediatric cardiac critical care institutions to support clinician education, scientific exchange, and awareness of fluid management strategies in critically ill children. Through these efforts, Nuwellis has helped foster dialogue around the growing clinical importance of fluid balance and the role of extracorporeal ultrafiltration therapies in pediatric intensive care settings.

GlobeNewsWire·Jun 25, 2026
Nuwellis Announces Pediatric Expansion in Michigan with First Aquadex SmartFlow® Installations

MINNEAPOLIS, June 25, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces its expansion in Michigan with the installation of three Aquadex SmartFlow® systems at a leading pediatric healthcare provider. This represents Nuwellis' first pediatric program in the state of Michigan and further expands the Company's growing presence in pediatric critical care into a significant healthcare market.

GlobeNewsWire·Jun 24, 2026
Incoming Nuwellis CEO Mike McCormick Underscores Strategic Priorities for Continued Market Expansion in Pediatric Category and Revenue Generation in Letter to Shareholders

MINNEAPOLIS, June 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, reviews the year-to-date and outlines strategic priorities in a Letter to Shareholders from newly appointed CEO, Mike McCormick.

GlobeNewsWire·Jun 18, 2026
Nuwellis Expands Critical Care Education with Aquadex Training at University of Minnesota Critical Care Cardiology Education Summit

MINNEAPOLIS, June 18, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, highlighted the clinical utility of its Aquadex SmartFlow® system at the 4th annual Critical Care Cardiology Education Summit (CCCES), hosted by the University of Minnesota. As part of the conference's skills-based curriculum, conference instructors conducted focused Aquadex training sessions that provided participants with practical experience using the Company's ultrafiltration technology.

GlobeNewsWire·Jun 16, 2026
Nuwellis Appoints Mike McCormick as Chief Executive Officer

Transition to become effective June 30, 2026; current CEO John Erb to continue as Chairman of the Board Transition to become effective June 30, 2026; current CEO John Erb to continue as Chairman of the Board

Peers Comparison

Key metrics vs top competitors for Nuwellis, Inc. (NUWE)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
NUWE logoNUWENuwellis, Inc.Current
$3.14$1.14M-0.12-5.38%-211.86%-382.81%—
NVCR logoNVCRNovoCure Limited
$15.78$1.8B-12.938.28%-25.66%-50.82%—
ANGO logoANGOAngioDynamics, Inc.
$13.08$540.45M-15.76-3.76%-10%-17.65%—
ATRC logoATRCAtriCure, Inc.
$29.73$1.51B-123.8814.88%-0.83%-0.95%—
CNMD logoCNMDCONMED Corporation
$32.76$1.01B21.705.16%4%5.4%—
MMSI logoMMSIMerit Medical Systems, Inc.
$69.45$4.14B32.6111.66%9.03%8.95%—

Compare NUWE vs Peers

Nuwellis, Inc. (NUWE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs NVCR

Most directly comparable listed peer for NUWE.

Scale Benchmark

vs ABT

Larger-name benchmark to compare NUWE against a more recognizable public peer.

Peer Set

Compare Top 5

vs NVCR, ANGO, ATRC, CNMD

NUWE SEC Filings & Documents

Nuwellis, Inc. (NUWE) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 12, 2026·SEC

Material company update

Apr 29, 2026·SEC

Material company update

Apr 24, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 11, 2026·SEC

FY 2025

Mar 11, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

May 15, 2026·SEC

FY 2025

Nov 12, 2025·SEC

FY 2025

Aug 14, 2025·SEC

Get notified when NUWE posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

NUWE Frequently Asked Questions

Nuwellis, Inc. (NUWE) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Nuwellis, Inc.'s revenue?

Nuwellis, Inc. (NUWE) reported $8.8M in revenue for fiscal year 2025. This represents a 37325% increase from $0.0M in 2004.

How fast is Nuwellis, Inc. growing?

Nuwellis, Inc. (NUWE) saw revenue decline by 5.4% over the past year.

Is NUWE profitable?

Nuwellis, Inc. (NUWE) reported a net loss of $18.8M for fiscal year 2025.

Dividend & Returns
What is NUWE's return on equity?

Nuwellis, Inc. (NUWE) has a return on equity (ROE) of -382.8%. Negative ROE indicates the company is unprofitable.

What is Nuwellis, Inc.'s free cash flow?

Nuwellis, Inc. (NUWE) had negative free cash flow of $11.5M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in NUWE back in 2004?

Total return calculator · dividends reinvested · 22+ years of data

See returns →